MetaVia Management
Management criteria checks 1/4
MetaVia's CEO is Hyung-Heon Kim, appointed in Aug 2023, has a tenure of 1.42 years. total yearly compensation is $1.01M, comprised of 17.2% salary and 82.8% bonuses, including company stock and options. directly owns 0.4% of the company’s shares, worth $73.83K. The average tenure of the management team and the board of directors is 1.4 years and 3.5 years respectively.
Key information
Hyung-Heon Kim
Chief executive officer
US$1.0m
Total compensation
| CEO salary percentage | 17.2% |
| CEO tenure | 1.4yrs |
| CEO ownership | 0.4% |
| Management average tenure | 1.4yrs |
| Board average tenure | 3.5yrs |
Recent management updates
Recent updates
Here's Why We're A Bit Worried About NeuroBo Pharmaceuticals' (NASDAQ:NRBO) Cash Burn Situation
Oct 03
NeuroBo Pharmaceuticals regains compliance with Nasdaq minimum bid price requirement
Sep 29Here's Why NeuroBo Pharmaceuticals (NASDAQ:NRBO) Must Use Its Cash Wisely
Sep 14NeuroBo Pharmaceuticals climbs higher on announcing reverse stock split
Sep 12NeuroBo Pharmaceuticals: Advancing Therapies For Viral, Neuropathic And Neurodegenerative Diseases
Nov 25NeuroBo on track to post a record gain after announcing a special meeting
Jun 14NeuroBo Pharmaceuticals rallies on ANA Therapeutics acquisition
Jan 06Here's What NeuroBo Pharmaceuticals, Inc.'s (NASDAQ:NRBO) Shareholder Ownership Structure Looks Like
Dec 21NeuroBo Pharmaceuticals EPS misses by $0.02
Nov 13CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$28m |
| Jun 30 2024 | n/a | n/a | -US$26m |
| Mar 31 2024 | n/a | n/a | -US$17m |
| Dec 31 2023 | US$1m | US$174k | -US$12m |
| Sep 30 2023 | n/a | n/a | -US$12m |
| Jun 30 2023 | n/a | n/a | -US$11m |
| Mar 31 2023 | n/a | n/a | -US$14m |
| Dec 31 2022 | US$61k | n/a | -US$14m |
| Sep 30 2022 | n/a | n/a | -US$14m |
| Jun 30 2022 | n/a | n/a | -US$14m |
| Mar 31 2022 | n/a | n/a | -US$15m |
| Dec 31 2021 | US$29k | n/a | -US$15m |
Compensation vs Market: Hyung-Heon's total compensation ($USD1.01M) is above average for companies of similar size in the US market ($USD642.68K).
Compensation vs Earnings: Hyung-Heon's compensation has increased whilst the company is unprofitable.
CEO
Hyung-Heon Kim (49 yo)
1.4yrs
Tenure
US$1,012,073
Compensation
Mr. Hyung-Heon Kim had been Independent Director of MetaVia Inc. (formerly known as NeuroBo Pharmaceuticals, Inc.) since July 09, 2021 until August 11, 2023 and serves as its Chief Executive Officer, Presi...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 1.4yrs | US$1.01m | 0.40% $ 73.8k | |
| Chief Financial Officer | 1.3yrs | US$154.50k | no data | |
| Chief Scientific Officer | 1.4yrs | no data | no data | |
| Senior Vice President of Clinical Operations | 1.4yrs | no data | no data |
1.4yrs
Average Tenure
Experienced Management: MTVA's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 3.5yrs | US$1.01m | 0.40% $ 73.8k | |
| Independent Director | 3yrs | US$110.71k | 0.11% $ 20.9k | |
| Independent Chairman of the Board | 3.5yrs | US$140.84k | 0.11% $ 20.9k | |
| Independent Director | 5.1yrs | US$102.36k | 0.11% $ 20.9k | |
| Chairman of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 1.7yrs | US$50.47k | 0.045% $ 8.4k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 5.1yrs | US$100.35k | 0.11% $ 20.9k | |
| Independent Director | 1.2yrs | US$21.93k | 0.029% $ 5.3k | |
| Member of Scientific Advisory Board | no data | no data | no data |
3.5yrs
Average Tenure
62.5yo
Average Age
Experienced Board: MTVA's board of directors are considered experienced (3.5 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/05 00:51 |
| End of Day Share Price | 2025/01/03 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
MetaVia Inc. is covered by 6 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Antonio Arce | H.C. Wainwright & Co. |
| Raghuram Selvaraju | H.C. Wainwright & Co. |
| Robert LeBoyer | Ladenburg Thalmann & Company |